We would welcome your comments on the draft paper entitled “All Wales Advice on SGLT-2 Inhibitors in Type 2 Diabetes and Cardiovascular Disease”.
This guidance has been developed to help support healthcare professionals in the prescribing of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and cardiovascular disease. This document includes a comprehensive review of the evidence for SGLT-2 inhibitor use in type 2 diabetes mellitus in relation to cardiovascular outcomes and provides recommendations on the role of SGLT-2 inhibitors in this patient population.
Please access the document below, add any comments to our consultation pro‑forma and send it to us at: firstname.lastname@example.org.
Closing date: Tuesday 18 May 2021